PositiveReview/Other2019
A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome
Classification Results
AI Classification
PositiveFine-tuned Classification
Positive